Investor Alert

New York Markets After Hours

Market Pulse Archives

Dec. 31, 2021, 8:53 a.m. EST

Xeris Biopharma soars on premarket leading volume after FDA approval of Cushing's syndrome treatment

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Xeris Biopharma Holdings Inc. (XERS)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Xeris Biopharma Holdings Inc. /zigman2/quotes/207093206/composite XERS -1.36% shot up 24.3% on heavy volume in premarket trading Friday toward a five-month high, after the biopharmaceutical company said its Recorlev has been approved by the U.S. Food and Drug Administration for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome, which is a potentially fatal endocrine disease. Trading volume ballooned to 4.4 million shares, enough to make the stock the most actively traded ahead of the open, and well above the full-day average of about 1.9 million shares. " With this approval, Xeris' experienced endocrinology-focused commercial organization can begin rapidly working to help address the needs of Cushing's syndrome patients in the U.S. who are treated with prescription therapy," said Chief Executive Paul Edick. The stock had run up 35.0% since closing at an 18-month low of $1.80 on Oct. 28 through Thursday, but had still plunged 51.6% year to date, while the iShares Biotechnology ETF /zigman2/quotes/206189322/composite IBB +0.50% had gained 1.5% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.01% had climbed 27.2%.

US : U.S.: Nasdaq
$ 2.17
-0.03 -1.36%
Volume: 1.25M
May 20, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$298.16 million
Rev. per Employee
US : U.S.: Nasdaq
$ 115.61
+0.58 +0.50%
Volume: 1.84M
May 20, 2022 4:00p
+0.57 +0.01%
Volume: 3.00B
May 20, 2022 5:03p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.